Theroux, P.

patient aspirin trial mortality aspirin dose disease death syndrome study platelet event /iiia trend lotrafiban infarction robert stroke randomized outcome aspirin doses 15 years hospital non-st-segment elevation point swets subs service all-cause mortality heart hazard university glycoprotein 15- year period therapy elevation signi angina bravo end point ischemic table group research treatment transfusion cerebrovascular disease receptor signi ficantly nste acs troponin month model 6- month mortality circulation david ն162 mg /day lotrafiban group merck investigator blood analysis figure cardiol placebo heparin management cerebrovascular in-hospital william ͻ162 mg /day result all-cause revascularization schering-plough period gusto change eli lilly ecg changes increase synergy non-st-segment